In metastatic melanomas carrying BRAF, the combination of BRAFi with MEK inhibitor and immunotherapy represents a further step forward and a pilot clinical study suggests its clinical efficacy [8]. This evidence concerns the gene MAP2K7 and metastatic melanoma.